Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services Limited informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 7-day suspension order for the drug license of a store located at SVN Colony, Guntur, Andhra Pradesh. The order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Guntur, and was received on February 25, 2026. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945. The company has stated a potential revenue loss of Rs 2.22 lakhs due to this suspension. This is a routine regulatory update filed under SEBI Listing Regulations disclosure requirements.
The financial impact is negligible at just Rs 2.22 lakhs, affecting only a single store for seven days, so it is unlikely to materially affect the stock price or shareholder value. It signals routine regulatory compliance activity rather than any systemic issue.